SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Wilma Rudolph

PatientWilma Rudolph
Date of birth1972-06-23
IdentifiersMRN HR-ML036-SYN; SSN (made up) 000-36-5170
Document date2026-07-29
AuthorGloria Haynes-Whitaker, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review three weeks after awake craniotomy, before radiotherapy with temozolomide. [S]

History of Present Illness

Ms. Rudolph returns three weeks after an awake left frontal craniotomy. The surgeons removed all of the enhancing tumor, stopping at the mapped language sites, and the MRI the next day showed no residual enhancing tumor. Her speech was slower for three days after surgery and then came back to normal; she went home on the third day, having had heparin injections in hospital to prevent clots. She has had no seizure. The right hand is nearly back to normal, though fine buttons are still slow. The physical therapist saw her a week ago and gave her a home exercise program and a cane for uneven ground. She is now on dexamethasone 2 mg twice a day. Her fingerstick glucose readings at home have been 140 to 180 mg/dL after meals, and she is thirsty in the evenings. The pathology is glioblastoma, IDH-wildtype, with MGMT promoter methylation, and the tumor board has reviewed it with Dr. Brzezinski. She has met the radiation oncologist and had her planning scan, and starts radiotherapy with temozolomide on Monday. She has had no thoughts of self-harm. [S]

ElementDetail
OperationAwake craniotomy with mapping; gross total resection of the enhancing tumor; home on day 3
PathologyGlioblastoma, IDH-wildtype, CNS WHO grade 4; TERT promoter mutation, EGFR amplification, +7/-10; MGMT promoter methylated
FunctionSpeech normal; right hand nearly normal; walking well
SteroidDexamethasone 2 mg twice a day; glucose up to 180 mg/dL after meals
NextRadiotherapy 60 Gy in 30 fractions with daily temozolomide from Monday

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired in the afternoons; appetite larger on the steroid; weight up 1.6 kg
NeurologicalPositiveFine buttons slow with the right hand; no headache, seizure or speech difficulty
EndocrinePositiveThirsty in the evenings; glucose 140 to 180 mg/dL after meals
MusculoskeletalNegativeNo difficulty rising from a chair or climbing stairs
IntegumentaryNegativeIncision healing; no redness or drainage
CardiovascularNegativeNo leg swelling or calf pain
PsychiatricNegativeMood steadier; PHQ-9 6; no thoughts of self-harm

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2026-06-29activeS
Dexamethasone 4 mg oral tablet, one tablet twice a day with food, for symptomatic vasogenic edema, until surgeryOne tablet twice a day with breakfast and lunchOral route2026-06-30 to 2026-07-08completedS
Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasoneOne tablet twice a dayOral route2026-06-30 to 2026-08-12completedS
Dexamethasone 2 mg oral tablet, one tablet twice a day after surgery, taperingOne tablet twice a dayOral route2026-07-10 to 2026-07-29completedS
Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stopOne tablet daily for a week, then half a tablet daily for a weekOral route2026-07-29 to 2026-08-12completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-29Body height180cmS
2026-07-29Body weight69.4kgS
2026-07-29Body mass index (BMI) [Ratio]21.4kg/m2S
2026-07-29Systolic blood pressure132mm[Hg]S
2026-07-29Diastolic blood pressure80mm[Hg]S
2026-07-29Heart rate76/minS
2026-07-29Respiratory rate14/minS
2026-07-29Body temperature36.6CelS
2026-07-29Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-29Hemoglobin [Mass/volume] in Blood12.6g/dL12-15.5 g/dLNormalS
2026-07-29Leukocytes [#/volume] in Blood by Automated count9.610*3/uL4-11 10*3/uLNormalS
2026-07-29Neutrophils [#/volume] in Blood by Automated count7.210*3/uL1.5-7.7 10*3/uLNormalS
2026-07-29Lymphocytes [#/volume] in Blood by Automated count1.110*3/uL1-4 10*3/uLNormalS
2026-07-29Platelets [#/volume] in Blood by Automated count24810*3/uL150-400 10*3/uLNormalS
2026-07-29Creatinine [Mass/volume] in Serum or Plasma0.82mg/dL0.59-1.04 mg/dLNormalS
2026-07-29Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M85mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-35 U/LNormalS
2026-07-29Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-35 U/LNormalS
2026-07-29Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-07-29Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2026-07-29Glucose [Mass/volume] in Serum or Plasma168mg/dL70-99 mg/dLHighS
2026-07-29Karnofsky Performance Status score90{score}S
2026-07-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S

Physical Exam

Vital signs recorded on 2026-07-29; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 69.4 kg; blood pressure 132/80, pulse 76
HeadLeft frontal incision healed, staples out; no swelling or fluid collection
Mental status and speechFluent, no word-finding pauses; naming and repetition intact
MotorNo pronator drift; right grip 5-/5, finger tapping slightly slow; hip flexors 5/5 on both sides; rises from a chair without using her arms
GaitSteady; tandem gait normal
ExtremitiesNo leg swelling; calves soft; left calf slightly smaller than the right
PsychiatricFocused and well informed; asks detailed questions

Problems

ProblemClinical statusVerificationCodeProvenance
Three weeks of headaches on waking, with ten days of pauses in finding words and clumsiness of the right hand, in a previously well woman of 54: an intracranial lesion must be excluded. MRI of the brain with and without contrast booked for tomorrow morning, and neuro-oncology review bookedresolvedconfirmed R29.818S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded when the MRI showed a brain mass.
Left posterior frontal ring-enhancing mass, 3.8 cm, with central necrosis, surrounding edema and 5 mm midline shift, next to the language and motor areas; presumed high-grade glioma, with no primary cancer elsewhere on CT; tissue diagnosis pendingresolvedconfirmed D49.6S — Synthetic imaging diagnosis before surgery; superseded by the pathology.
Glioblastoma, IDH-wildtype, CNS WHO grade 4, left posterior frontal lobe, MGMT promoter methylated, after gross total resection of the enhancing tumor; synthetic modern detail linked to her publicly reported brain canceractiveconfirmed C71.1S — Synthetic histology, molecular result and location; brain cancer is documented as the cause of her death (D), and nothing more about it was made public.
Late effects of childhood poliomyelitis: paralysis of the left leg in early childhood, treated with a metal brace, a special shoe, massage and heat, with full recovery of walking by about age 12 and a later career as an Olympic sprinter; no new weakness, fatigue or pain now to suggest post-polio syndromeactiveconfirmed B91S — Documented childhood polio (D); the current absence of new symptoms is synthetic.
Vasogenic cerebral edema around the left frontal mass, with 5 mm midline shift, causing headache and contributing to the language and right-hand symptoms; treated with dexamethasoneactiveconfirmed G93.6S — Synthetic finding on the first MRI.
Steroid-induced hyperglycemia on dexamethasone: random glucose 168 mg/dL, with an A1c of 5.6% before steroidsactiveconfirmed R73.9S — Synthetic common effect of dexamethasone; resolved after the taper.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryIntegrated WHO CNS5 diagnosisOn the surgical specimenUp to dateGlioblastoma, IDH-wildtype, CNS WHO grade 4: IDH1 R132H negative and no IDH1 or IDH2 mutation on sequencing; ATRX retained; TERT promoter mutation; EGFR amplification; +7/-10; CDKN2A deleted; H3 and BRAF wild-type
LaboratoryMGMT promoter methylationOn the surgical specimenUp to dateMethylated
ImagingMRI within 48 hours of surgeryAfter resection, as the baseline for radiotherapy planningUp to dateThe day after surgery: no residual enhancing tumor
LaboratoryBlood count with neutrophils, lymphocytes and plateletsBaseline before temozolomideCompleted todayHemoglobin 12.6 g/dL, white cells 9.6, neutrophils 7.2, lymphocytes 1.1, platelets 248
LaboratoryKidney and liver testsBaseline before temozolomideCompleted todayCreatinine 0.82 mg/dL, eGFR 85; ALT 28, AST 22 U/L, bilirubin 0.5 mg/dL, albumin 4.0 g/dL
LaboratoryGlucose on dexamethasoneAt each visit while on a steroidCompleted today168 mg/dL random; home readings 140 to 180 after meals
LaboratoryHepatitis B, hepatitis C and HIV screeningBefore chemotherapyOrderedDrawn today
Medication safetyDexamethasone taperAs soon as symptoms allow after surgeryCompleted today2 mg twice a day now; 2 mg daily for a week, 1 mg daily for a week, then stop
Medication safetyPneumocystis pneumonia prophylaxisThroughout concurrent temozolomideOrderedSulfamethoxazole-trimethoprim three times a week from the first day
Medication safetyAntiemetic before temozolomideEach doseOrderedOndansetron 30 to 60 minutes before the bedtime dose, on an empty stomach
Medication safetySeizure history and antiseizure drug needEach visitNot indicatedNo seizure before or after surgery; no antiseizure drug
ExaminationNeurologic examination (language, strength, gait)Each visitCompleted todaySpeech normal; right grip 5-/5 with slightly slow finger tapping; gait steady
ExaminationSigns of leg clot or pulmonary embolismEach visitCompleted todayNo leg swelling or calf tenderness; hospital prophylaxis given after surgery; no routine prophylaxis at home
SurveyPerformance status (Karnofsky)Each visitCompleted todayKarnofsky 90
ReferralPhysical therapyAfter surgery when weakness or fall risk is presentUp to dateAssessed a week ago: home program and a cane for uneven ground
ReferralRadiation oncology and clinical trial screeningAfter the integrated diagnosisUp to datePlanning scan done; no eligible trial open
Self-managementFalls, leg strength and late effects of polioEach visitCompleted todayNo falls; legs 5/5; no new weakness, fatigue or pain in the polio-affected leg
SurveyDistress and depression screen (PHQ-9)At diagnosis, each treatment phase, and when symptoms changeCompleted todayPHQ-9 6; no thoughts of self-harm

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026); Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18(3):170-186 (PMID 33293629) (2021); Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231-1251 (PMID 34185076) (2021); Mohile NA, et al. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. J Clin Oncol 2022;40(4):403-426 (PMID 34898238) (2022); Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996 (PMID 15758009) (2005); Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003 (PMID 15758010) (2005); Wen PY, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 2023 (PMID 37774317) (2023); TEMODAR (temozolomide) capsules, prescribing information (2026); Walbert T, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 2021;23(11):1835-1844 (PMID 34174071) (2021); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Farbu E, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Eur J Neurol 2006;13(8):795-801 (PMID 16879288) (2006); CMID: Clinical Monitoring Intelligence Database, depression monograph (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Radiotherapy with temozolomide from Monday for six weeks, with weekly blood counts at the radiation clinic. Primary care review at the end of radiotherapy. Call for fever, bruising, a seizure, new weakness or headache. Next scheduled visit 2026-09-14: end of six weeks of radiotherapy with daily temozolomide: blood counts, liver tests, Pneumocystis prophylaxis, fatigue, mood, tumor-treating fields and an early palliative care referral. [S]